Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD117-CAR-iNKT cells
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD117-CAR-iNKT cells are a form of adoptive cell therapy in which invariant natural killer T (iNKT) cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting CD117, also known as the KIT receptor. The primary mechanism involves redirecting the cytotoxic activity of iNKT cells specifically against tumor or malignant hematopoietic stem/progenitor cells that express CD117. This approach is being investigated for advanced systemic mastocytosis and acute myeloid leukemia (AML), where the KIT D816V mutation is common. Preclinical studies have shown that these engineered iNKT or T-cells can effectively kill KIT D816V-positive tumor and patient-derived mast cell lines in vitro and reduce tumor burden in vivo, with increased survival observed in animal models. However, there is concern about potential collateral damage to healthy hematopoietic stem/progenitor populations due to their expression of CD117[3][1].
- Other names
- anti-CD117 CAR iNKT cellsanti-CD-117 CAR iNKT cellsanti-CD 117 CAR iNKT cellsKIT-receptor CAR iNKT cells
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on CD117-CAR-iNKT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD117-CAR-iNKT cells.